Fibrocytic breast disease: current status of diagnosis and treatment.
Improved diagnostic procedures and use of a new steroidal agent, danazol (Danocrine), should reduce the need for surgical intervention in fibrocystic breast disease. Thermography, a non-invasive procedure that may be used with impunity, may help identify women at high risk. Mammography, which is useful in revealing malignancy in an early stage, should be done in women with tow consecutive abnormal thermograms. Biopsies should be performed, however, on suspicious, firm, irregular masses, regardless of results on thermography or mammography. Use of danazol may be advantageous not only in ameliorating pain and eliminating nodosities, but also in guiding the surgeon to the nodule that is unresponsive to treatment and therefore should be evaluated by biopsy.
D000328:Adult; D000368:Aged; D001707:Biopsy, Needle; D001941:Breast Diseases / Q000175:diagnosis* / Q000628:therapy*; D003581:Cytodiagnosis; D003613:Danazol / Q000627:therapeutic use; D005260:Female; D005348:Fibrocystic Breast Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D013396:Suction; D013817:Thermography
D003613:Danazol